Gilead Just Reclaimed $150. The Bigger Target Is $165
$Gilead Sciences(GILD)$
$Gilead Sciences (GILD) +2.17%: Momentum Builds Toward $157 High, $151 Pivot in Focus
Latest Close: $150.89 (+3.21) — just 4.1% below the 52-week high of $157.29. Volume surged to 7.84M shares (1.58x ratio), confirming institutional accumulation.
Core Market Drivers: Gilead's HIV franchise continues to anchor sentiment following recent FDA approvals (Bixlenvo, Trodelvy). The stock rebounded sharply from early-September biotech sector weakness, with strong Q2 results ($7.80B revenue beat) still underpinning the recovery narrative.
Technical Analysis: 📊 RSI-6 at 70.5 signals strong bullish momentum but nears overbought territory; RSI-12 at 64.1 confirms medium-term strength. MACD histogram is negative (-1.85) but rising rapidly, with DIF at 2.59 approaching the DEA line — a bullish crossover may be imminent. KDJ shows J at 84.4, indicating extended short-term upside.
Key Price Levels:
-
Primary Support: $132.73 (Sept 16 low)
-
Strong Resistance: $157.29 (52-week high)
-
Immediate Pivot: $150.32 — a sustained close above this opens the path to $157–$165
Valuation Perspective: 📌 P/E TTM of -57.7 reflects recent non-cash impairment charges; Forward P/E is deeply negative due to accounting adjustments. P/S of 6.15 remains above biotech peers, while dividend yield of 2.13% provides income support.
Analyst Targets: 🎯 31 analysts with an average target of $158.53 (range $123–$180). Ratings: 7 Strong Buy, 18 Buy, 6 Hold — bullish institutional consensus with ~5% upside implied.
Weekly Outlook: 🔮 Expect a range of $146.50–$156.00. A breakout above $151.04 (today's high) targets $157.29, then $165. Failure to hold $146.89 risks a pullback to $142–$138.
⚠️ Risk Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Past performance does not guarantee future results.
🎯$Gilead Sciences (GILD) Options Strategy: Bull Call Spread
-
Underlying: GILD
-
View: Cautiously bullish — momentum building toward $157 resistance; supported by institutional accumulation and bullish analyst consensus
-
Strategy Type: Debit spread (defined risk, directional bullish)
-
Option Contract Portfolio:
-
Buy 1x GILD 2026-11-20 $150 Call @ ~$5.76 (mid from bulk order flow)
-
Sell 1x GILD 2026-11-20 $165 Call @ ~$1.58 (mid from bulk order flow)
-
-
Max Gain & Loss:
-
Max Gain: $10.82 per share (=$15 width − $4.18 net debit)
-
Max Loss: $4.18 per share (net debit paid)
-
-
Initial Cost/Debit: $4.18 net debit (per share)
Markets are always moving - and sometimes, the best move is knowing what works for you.
With Treasury yields, oil prices and rate expectations keeping markets on edge this week, investors are once again thinking carefully about where to position next. There’s no one-size-fits-all choice in investing — and the same goes for Tiger Merch. This month’s hot picks are in, featuring the Tiger Toiletry Bag, Universal Travel Adapter, Tiger Umbrella and more favourites chosen by fellow Tigers.
Explore the Monthly Hot Picks in Tiger Coin Mall, now 12% OFF for a limited time.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
